Spots Global Cancer Trial Database for xmab20717
Every month we try and update this database with for xmab20717 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05005728 | Metastatic Cast... | vudalimab + car... vudalimab + ola... vudalimab monot... vudalimab + doc... vudalimab + cab... | 18 Years - | Xencor, Inc. | |
| XmAb20717 in Advanced Biliary Tract Cancers | NCT05297903 | Biliary Tract C... | XmAb20717 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | NCT05337735 | Microsatellite ... Peritoneal Meso... Extrapulmonary ... Neuroendocrine ... Cervical Carcin... Hodgkin's Lymph... Pleural Mesothe... Small Cell Lung... | XmAb20717 | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | NCT06173505 | Nonsquamous Non... | Vudalimab + Car... Pembrolizumab +... | 18 Years - | Xencor, Inc. | |
| XmAb20717 in Advanced Biliary Tract Cancers | NCT05297903 | Biliary Tract C... | XmAb20717 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | NCT05032040 | Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast... | vudalimab | 18 Years - | Xencor, Inc. | |
| Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | NCT05900648 | Colorectal Canc... Colon Cancer Rectum Cancer | Regorafenib XmAb20717 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | NCT05032040 | Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast... | vudalimab | 18 Years - | Xencor, Inc. | |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05005728 | Metastatic Cast... | vudalimab + car... vudalimab + ola... vudalimab monot... vudalimab + doc... vudalimab + cab... | 18 Years - | Xencor, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
